PMID

Data

Article Title

Organization

N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase.

Pharmaceutical Research Institute

Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.

Pharmaceutical Research Institute

Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors.

Pharmaceutical Research Institute

Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).

Pharmaceutical Research Institute

Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe.

Pharmaceutical Research Institute

Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.

Pharmaceutical Research Institute

Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.

Pharmaceutical Research Institute

Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators.

Pharmaceutical Research Institute

An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes.

Pharmaceutical Research Institute

Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.

Pharmaceutical Research Institute

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

Pharmaceutical Research Institute

Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.

Pharmaceutical Research Institute

Pyrrolopyridazine MEK inhibitors.

Pharmaceutical Research Institute

A new class of high affinity thyromimetics containing a phenyl-naphthylene core.

Pharmaceutical Research Institute

Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.

Pharmaceutical Research Institute

Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.

Pharmaceutical Research Institute

Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.

Pharmaceutical Research Institute

Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.

Pharmaceutical Research Institute

Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).

Pharmaceutical Research Institute

Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.

Pharmaceutical Research Institute

Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase.

Pharmaceutical Research Institute

Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.

Pharmaceutical Research Institute

Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.

Pharmaceutical Research Institute

Design, synthesis, and biological evaluation of novel bifunctional thyrointegrin antagonists for neuroblastoma.

Pharmaceutical Research Institute

Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol.

Pharmaceutical Research Institute

Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.

Pharmaceutical Research Institute

Glycine alpha-ketoamides as HCV NS3 protease inhibitors.

Pharmaceutical Research Institute

Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives.

Pharmaceutical Research Institute

Dihydropyridine neuropeptide Y Y(1) receptor antagonists.

Pharmaceutical Research Institute

Retinoic acid receptor beta,gamma-selective ligands: synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids.

Pharmaceutical Research Institute

Buspirone analogues as ligands of the 5-HT1A receptor. 1. The molecular structure of buspirone and its two analogues.

Pharmaceutical Research Institute